{"product_id":"axsome-bcg-matrix","title":"Axsome Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic potential of Axsome's product portfolio with a glimpse into their BCG Matrix. See where their key offerings might be positioned as Stars, Cash Cows, Dogs, or Question Marks. For a comprehensive understanding and actionable strategic insights, dive into the full BCG Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuvelity (Major Depressive Disorder)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAuvelity is a standout performer for Axsome, positioned as a star in the company's portfolio due to its remarkable sales trajectory.  The drug's significant year-over-year growth underscores its strong market penetration in the major depressive disorder treatment landscape.\u003c\/p\u003e\n\u003cp\u003eIn the fourth quarter of 2024, Auvelity achieved net product sales of approximately $92.6 million. For the entirety of 2024, sales reached an impressive $291.4 million, marking an 89% and 124% increase respectively compared to the previous year.\u003c\/p\u003e\n\u003cp\u003eThis robust financial performance, coupled with a consistent rise in prescription volume, solidifies Auvelity's status as a high-growth product in a dynamic and expanding market for depression therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSymbravo (Acute Migraine Treatment)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSymbravo, approved by the FDA in January 2025 for acute migraine treatment, is positioned as a potential blockbuster by Axsome. Its anticipated June 2025 commercial launch targets a significant market opportunity, driven by a novel mechanism and superior efficacy compared to current options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAXS-05 (Alzheimer's Disease Agitation)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAXS-05, targeting agitation associated with Alzheimer's disease, has successfully concluded its Phase 3 trials, demonstrating promising outcomes.  The U.S. Food and Drug Administration (FDA) has recognized its potential by granting it Breakthrough Therapy designation, highlighting the significant unmet need in this therapeutic area.\u003c\/p\u003e\n\u003cp\u003eAxsome Therapeutics anticipates submitting a supplemental New Drug Application (sNDA) for AXS-05 in the third quarter of 2025. This strategic move aims to establish AXS-05 as a leading treatment option for Alzheimer's disease agitation, a market segment with substantial growth potential and a clear need for innovative therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAXS-12 (Narcolepsy with Cataplexy)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAXS-12 is positioned as a potential Star in Axsome's portfolio, reflecting its strong performance and market prospects.  The drug has achieved positive topline results in Phase 3 trials for narcolepsy with cataplexy.  Axsome Therapeutics anticipates submitting a New Drug Application (NDA) for AXS-12 in the latter half of 2025.\u003c\/p\u003e\n\u003cp\u003eThe narcolepsy market is experiencing significant growth, and AXS-12's demonstrated efficacy suggests it could capture a substantial portion of this expanding market. This positions AXS-12 favorably for future success, potentially becoming a leading treatment option.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAXS-12 Phase 3 Results:\u003c\/strong\u003e Positive topline data has been reported for narcolepsy with cataplexy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNDA Submission Timeline:\u003c\/strong\u003e Axsome expects to file an NDA in the second half of 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Potential:\u003c\/strong\u003e The growing narcolepsy market and AXS-12's efficacy indicate strong market share potential.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStar Classification:\u003c\/strong\u003e These factors support AXS-12's classification as a Star within the BCG matrix.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolriamfetol (ADHD in Adults)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSolriamfetol, currently a Question Mark for Axsome in the ADHD market, showed promising results in the Q1 2025 FOCUS Phase 3 trial for adult ADHD. \u003c\/p\u003e\n\u003cp\u003ePositive trial outcomes and successful market entry could elevate solriamfetol to Star status, capitalizing on a potentially significant unmet need in adult ADHD treatment. \u003c\/p\u003e\n\u003cp\u003eThe ADHD drug market is substantial, with global sales projected to reach over $25 billion by 2030, offering a lucrative opportunity for new entrants with demonstrated efficacy.\u003c\/p\u003e\n\u003cp\u003eAxsome's strategic positioning of solriamfetol hinges on its ability to secure regulatory approval and differentiate itself in a competitive landscape, potentially capturing a notable market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxsome's Top Performers: High Growth, High Stakes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars in Axsome's portfolio represent products with high market share and high growth potential, demanding significant investment to maintain their leading position. Auvelity exemplifies this, showing substantial revenue growth and market penetration. AXS-12 also fits this category, with positive trial data and a strong market outlook in narcolepsy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMarket Growth\u003c\/th\u003e\n\u003cth\u003eMarket Share\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eGrowth vs. Prior Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuvelity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e$291.4 million\u003c\/td\u003e\n\u003ctd\u003e124%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAXS-12\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eProjected High\u003c\/td\u003e\n\u003ctd\u003eN\/A (Pre-launch)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Axsome BCG Matrix analyzes its product portfolio by market share and growth, guiding investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA visual Axsome BCG Matrix clarifying portfolio balance, relieving the pain of strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSunosi (Excessive Daytime Sleepiness in Narcolepsy or OSA)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSunosi, a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea, is a key Cash Cow for Axsome.  It consistently brings in revenue, with Q4 2024 net product revenue reaching approximately $25.7 million. \u003c\/p\u003e\n\u003cp\u003eFor the entirety of 2024, Sunosi generated $93.8 million in net product revenue, demonstrating its reliable performance. While its growth may not match newer products, its established market position ensures steady cash flow for the company. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Payer Coverage for Sunosi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSunosi demonstrates robust payer coverage, reaching approximately 83% of all covered lives across various healthcare channels. This widespread access, particularly the 95% coverage within the commercial sector, solidifies its position as a Cash Cow by ensuring a consistent and reliable revenue stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsistent Prescription Numbers for Sunosi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSunosi demonstrates consistent prescription performance, nearing 46,000 prescriptions in the first quarter of 2025. This steady demand, within a well-established market, solidifies its role as a dependable revenue stream for Axsome.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower Investment Needs for Sunosi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSunosi, as a product in a mature market, typically demands less investment in marketing and distribution compared to newer, high-growth offerings. This strategic positioning allows Axsome to capitalize on its existing market share without significant incremental spending. \u003c\/p\u003e\n\u003cp\u003eThis lower investment requirement enables Axsome to effectively 'milk' the revenue generated by Sunosi. The company can then reallocate these freed-up capital resources to nurture and advance its promising pipeline assets, fostering future growth. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMature Market Position:\u003c\/strong\u003e Sunosi operates in a well-established market, meaning its promotional and placement costs are generally lower than those for products entering high-growth sectors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePassive Revenue Generation:\u003c\/strong\u003e Axsome can leverage Sunosi to generate consistent revenue with minimal ongoing investment, a classic 'cash cow' strategy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResource Reallocation:\u003c\/strong\u003e The cash flow from Sunosi can be strategically channeled into research and development for Axsome's pipeline, supporting future innovation and market expansion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024 Financial Context:\u003c\/strong\u003e While specific 2024 figures for Sunosi's investment needs are proprietary, Axsome's overall R\u0026amp;D expenditure in 2023 was $459 million, highlighting the company's commitment to pipeline development, which cash flow from established products like Sunosi helps to support.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for Pipeline Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSunosi, a key product for Axsome Therapeutics, serves as a vital Cash Cow, generating consistent revenue that underpins the company's growth strategy.\u003c\/p\u003e\n\u003cp\u003eThe reliable cash flow from Sunosi is instrumental in financing Axsome's ongoing research and development, particularly for its promising late-stage pipeline candidates. This financial backing is crucial for advancing potential future Stars and Question Marks, showcasing the essential role of a Cash Cow in a diversified portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSunosi's Revenue Contribution:\u003c\/strong\u003e In the first quarter of 2024, Axsome reported $59.4 million in net sales for Sunosi, a significant increase from $34.5 million in the same period of 2023, highlighting its growing market presence and cash-generating ability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D Investment:\u003c\/strong\u003e Axsome's total R\u0026amp;D expenses for Q1 2024 were $169.6 million, a substantial portion of which is supported by the stable income from established products like Sunosi.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Support:\u003c\/strong\u003e The financial stability provided by Sunosi enables Axsome to commit resources to developing novel treatments, such as its pipeline candidates for Alzheimer's disease and migraine, positioning them for future growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSunosi: Axsome's Steady Revenue Stream \u0026amp; Strategic Investment Driver\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSunosi continues to be a cornerstone Cash Cow for Axsome, demonstrating consistent financial performance and market stability. Its role is crucial in funding the company's innovative pipeline. \u003c\/p\u003e\n\u003cp\u003eThe product's established market presence and strong payer coverage, reaching approximately 83% of covered lives, ensure a predictable and substantial revenue stream. This allows Axsome to strategically invest in future growth opportunities.\u003c\/p\u003e\n\u003cp\u003eSunosi's ability to generate passive revenue with lower investment needs allows Axsome to effectively reallocate capital towards its promising drug candidates, supporting overall portfolio development.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eBCG Category\u003c\/th\u003e\n\u003cth\u003e2024 Net Product Revenue (Approx.)\u003c\/th\u003e\n\u003cth\u003eQ1 2025 Prescriptions (Approx.)\u003c\/th\u003e\n\u003cth\u003ePayer Coverage (Approx.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSunosi\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003e$93.8 million\u003c\/td\u003e\n\u003ctd\u003e~46,000\u003c\/td\u003e\n\u003ctd\u003e~83%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAxsome BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact Axsome BCG Matrix report you will receive after purchase, offering a complete and uncompromised strategic analysis. This document is fully formatted and ready for immediate application in your business planning and decision-making processes. You can trust that no watermarks or demo content will be present in the final file delivered to you. This comprehensive report is designed to provide actionable insights into Axsome's product portfolio, enabling you to identify growth opportunities and manage resources effectively.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611042562425,"sku":"axsome-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/axsome-bcg-matrix.png?v=1754749929","url":"https:\/\/growthsharematrix.com\/products\/axsome-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}